Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer - 13/01/23
Abstract |
Epigenetics is an emerging mechanism for tumorigenesis. Treatment that targets epigenetic regulators is becoming an attractive strategy for cancer therapy. The role of epigenetic therapy in prostate cancer (PCa) remains elusive. Previously we demonstrated that upregulation of histone lysine demethylase KDM4B correlated with the appearance of castration resistant prostate cancer (CRPC) and identified a small molecular inhibitor of KDM4B, B3. In this study, we further investigated the role of KDM4B in promoting PCa progression and tested the efficacy of B3 using clinically relevant PCa models including PCa cell line LNCaP and 22Rv1 and xenografts derived from these cell lines. In loss and gain-functional studies of KDM4B in PCa cells, we found that overexpression of KDM4B in LNCaP cells enhanced its tumorigenicity whereas knockdown of KDM4B in 22Rv1 cells reduced tumor growth in castrated mice. B3 suppressed the growth of 22Rv1 xenografts and sensitized tumor to anti-androgen receptor (AR) antagonist enzalutamide inhibition. B3 also inhibited 22Rv1 tumor growth synergistically with rapamycin, leading to cell apoptosis. Comparative transcriptomic analysis performed on KDM4B knockdown and B3-treated 22Rv1 cells revealed that B3 inhibited both H3K9me3 and H3K27me3 demethylase activities. Our studies establish KDM4B as a target for CRPC and B3 as a potential therapeutic agent. B3 as monotherapy or in combination with other anti-PCa therapeutics offers proof of principle for the clinical translation of epigenetic therapy targeting KDMs for CRPC patients.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | KDM4B is a therapeutic target for castration-resistant prostate cancer (CRPC). |
• | KDM4 inhibitor B3 inhibits tumor growth in pre-clinical mouse model of CRPC. |
• | KDM4 inhibitor B3 sensitises CRPC to AR inhibitor enzalutamide inhibition. |
• | KDM4 inhibitor B3 synergistically inhibits CRPC with mTOR inhibitor rapamycin. |
Keywords : Histone lysine demethylase, KDM4B, KDM inhibitor, Castration-resistant prostate cancer, Prostate cancer therapy
Plan
Vol 158
Article 114077- février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?